Affiliated with a Castle Connolly Top Hospital
Who is Dr. Telli, Medical Oncologist in Stanford, CA?
Dr. Melinda Telli, MD is a Medical Oncologist, who primarily practices in Stanford, CA with 1 additional practice location. She is board certified by the American Board of Internal Medicine. Dr. Telli completed her residency at Stanford University, Internal Medicine. Dr. Telli is fluent in English and Turkish, and is currently seeing new patients. Dr. Telli’s practice accepts Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare, Aetna, Cigna and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Telli’s office.
What are Areas of Expertise for Dr. Telli?
Dr. Melinda Telli, MD is a highly-rated, board-certified Medical Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions or procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Telli empowers patients to confidently navigate their health journey, specializing in Breast Cancer, Breast Cancer Genetics, Hereditary Cancer, or comprehensive wellness support. Serving the Stanford/CA community, Dr. Telli is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Telli go to medical school and complete their residency?
Fellowship: Stanford University Medical Oncology | Stanford University School of Medicine CA | Stanford University School of Medicine,Stanford, Ca, United States
Residency: Stanford University, Internal Medicine | Stanford University Medical Center
Is Dr. Telli board certified in Medical Oncologist?
Yes, Dr. Melinda Telli, MD is board certified by the American Board of Internal Medicine , American Board of Internal Medicine since 2008, American Board of Internal Medicine since 2005
What languages does Dr. Telli speak?
Dr. Telli and their clinical team can communicate with patients in the following languages:
English
Turkish
What conditions does Dr. Telli treat?
As a Medical Oncologist, Dr. Telli diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Telli. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Breast Cancer
- Upper-Outer Quadrant Right Female Breast Cancer
- Right Female Nipple and Areola Breast Cancer
- Left Female Nipple and Areola Breast Cancer
- Upper-Inner Quadrant Right Female Breast Cancer
- Widespread Left Female Breast Cancer
- Upper-Inner Quadrant Left Female Breast Cancer
- Central Right Female Breast Cancer
- Lower-Inner Quadrant Right Female Breast Cancer
- Female Breast Cancer
- Malignant Breast Tumor
- Breast Carcinoma
- Mammary cancer
- Breast carcinoma
- Breast tumor
- Right female breast cancer upper-outer
- Upper-outer right female breast tumor
- Malignant growth in upper-outer right female breast
- Cancer of right female nipple
- Right female areola tumor
- Malignant growth on right female nipple
- Cancer of left female nipple
- Left female areola tumor
- Malignant growth on left female nipple
- Right female breast cancer upper-inner
- Upper-inner right female breast tumor
- Malignant growth in upper-inner right female breast
- Left female breast cancer in multiple areas
- Diffuse left female breast cancer
- Malignant growth in overlapping sites of left female breast
- Left female breast cancer upper-inner
- Upper-inner left female breast tumor
- Malignant growth in upper-inner left female breast
- Right female breast central tumor
- Malignant growth in central right female breast
- Right female breast cancer lower-inner
- Lower-inner right female breast tumor
- Malignant growth in lower-inner right female breast
ICD-10 Codes:
- C50919: Malignant neoplasm of unspecified site of unspecified female breast
- C50911: Malignant neoplasm of unspecified site of right female breast
- C50912: Malignant neoplasm of unspecified site of left female breast
- C50412: Malignant neoplasm of upper-outer quadrant of left female breast
- C50411: Malignant neoplasm of upper-outer quadrant of right female breast
- C50011: Malignant neoplasm of nipple and areola, right female breast
- C50012: Malignant neoplasm of nipple and areola, left female breast
- C50211: Malignant neoplasm of upper-inner quadrant of right female breast
- C50812: Malignant neoplasm of overlapping sites of left female breast
- C50212: Malignant neoplasm of upper-inner quadrant of left female breast
- C50811: Malignant neoplasm of overlapping sites of right female breast
- C50111: Malignant neoplasm of central portion of right female breast
- C50311: Malignant neoplasm of lower-inner quadrant of right female breast
Also known as:
- Personal History of Breast Cancer
- Breast Cancer
- Past breast cancer
- Previous mammary malignancy
- History of breast tumor
ICD-10 Codes:
- Z853: Personal history of malignant neoplasm of breast
Also known as:
- Secondary Bone Cancer
- Secondary Brain Cancer
- Bone Cancer
- Brain Tumor
- Metastatic bone cancer
- Cancer spread to bone
- Bone metastases
- Metastatic brain cancer
- Brain metastases
- Cancer spread to brain
ICD-10 Codes:
- C7951: Secondary malignant neoplasm of bone
- C7931: Secondary malignant neoplasm of brain
Also known as:
- Mammogram for Breast Cancer Screening
- Health Screening
- Mammography
- Breast Cancer Screening (PDQ®)
- Mammograms
- Breast X-ray
- Breast Cancer Check
ICD-10 Codes:
- Z1231: Encounter for screening mammogram for malignant neoplasm of breast
Also known as:
- Follow-up After Treatment (Non-Cancer)
- Post-Treatment Check-up
- Aftercare Visit
- Recovery Monitoring Exam
ICD-10 Codes:
- Z09: Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm
Also known as:
- Cancer Spread to Liver and Bile Duct
- Liver Cancer
- Metastatic Liver Cancer
- Secondary Liver Tumor
- Liver Metastasis
ICD-10 Codes:
- C787: Secondary malignant neoplasm of liver and intrahepatic bile duct
Also known as:
- Genetic Disease Carrier Screening
- Genetic Testing
- Health Screening
- Genetic Carrier Test
- Hereditary Disease Carrier Screening
- Preconception Genetic Screening
ICD-10 Codes:
- Z1371: Encounter for nonprocreative screening for genetic disease carrier status
Which procedures does Dr. Telli perform as a Medical Oncologist?
As a Medical Oncologist, procedures performed by a Dr. Melinda Telli may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Telli's office.
Does Dr. Telli accept my insurance?
Dr. Telli accepts most major insurance plans. Important: Please call our office at before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Telli accept in Stanford, CA?
Dr. Telli in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Central California Alliance for Health
CVS Health (formerly Aetna)
Express Scripts
Medicaid
Medicare
Santa Clara Family Health Plan
State of California
UnitedHealthcare
View All Insurances
Where is Dr. Telli's office located?
Recognitions
Awards
Susan G. Komen for the Cure
Career Catalyst Research Award
Stanford University School of Medicine
Oncology Division Teaching Award
American Society of Clinical Oncology
Young Investigator Award
Susan G. Komen for the Cure
Fellowship Award
American Society of Clinical Oncology
Merit Award
Stanford Cancer Institute
New Investigator Award
Publications
Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer
JOURL OF CLINICAL ONCOLOGY, 2013
Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?
JOURL OF CLINICAL ONCOLOGY, 2012
Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians
JOURL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
ANLS OF ONCOLOGY, 2008
Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
JOURL OF CLINICAL ONCOLOGY, 2007
Dymic contrast-enhanced MRI
Jourl of the American Medical Informatics Association, 2013
Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2012
Single Cell Profiling of Circulating Tumor Cells
PLOS ONE, 2012
Prevalence, putative mechanisms
ture and science of sleep, 2012
Trastuzumab-Related Cardiac Dysfunction
JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2011
Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California
JOURL OF CLINICAL ONCOLOGY, 2010
Phyllodes tumors of the breast: tural history, diagnosis, and treatment.
Jourl of the tiol Comprehensive Cancer Network, 2007
Epidermal growth factor
BIOCHEMICAL PHARMACOLOGY, 1999
Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer
JOURNAL OF CLINICAL ONCOLOGY, 2013
Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?
JOURNAL OF CLINICAL ONCOLOGY, 2012
PARP inhibitors in cancer: moving beyond BRCA
LANCET ONCOLOGY, 2011
Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
BREAST CANCER RESEARCH AND TREATMENT, 2011
Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
ANNALS OF ONCOLOGY, 2008
Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
JOURNAL OF CLINICAL ONCOLOGY, 2007
Patient-derived xenografts of triple
Breast cancer research : BCR, 2014
(18)F-FPPRGD2 PET/CT: Pilot Phase Evaluation of Breast Cancer Patients.
Radiology, 2014
Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
American Society of Clinical Oncology educational book / ASCO. America, 2014
Single cell mutational analysis of PIK3CA in circulating tumor cells
BMC cancer, 2014
Dynamic contrast-enhanced MRI
Journal of the American Medical Informatics Association, 2013
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
BREAST CANCER RESEARCH AND TREATMENT, 2013
Qualitative and quantitative image-based biomarkers of therapeutic response in triple
AMIA Summits on Translational Science proceedings AMIA Summit on Trans, 2013
Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012
Breast cancer phenotype in women with TP53 germline mutations
BREAST CANCER RESEARCH AND TREATMENT, 2012
Single Cell Profiling of Circulating Tumor Cells
PLOS ONE, 2012
Prevalence, putative mechanisms
Nature and science of sleep, 2012
Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?
HEART FAILURE CLINICS, 2011
Trastuzumab-Related Cardiac Dysfunction
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011
PARP inhibitors in breast cancer.
Clinical advances in hematology & oncology : H&O, 2010
Novel Treatment Approaches for Triple-Negative Breast Cancer
CLINICAL BREAST CANCER, 2010
Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California
JOURNAL OF CLINICAL ONCOLOGY, 2010
Longer Relative Telomere Length in Blood from Women with Sporadic
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010
First-Line Chemotherapy for Metastatic Breast Cancer
CLINICAL BREAST CANCER, 2009
Phyllodes tumors of the breast: natural history, diagnosis, and treatment.
Journal of the National Comprehensive Cancer Network, 2007
Epidermal growth factor
BIOCHEMICAL PHARMACOLOGY, 1999
What is Dr. Telli's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Telli's National Provider Identifier (NPI) number is 1932135290.
What common questions do patients ask about Dr. Telli?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Telli
What is Dr. Melinda Telli's specialty?
Dr. Telli is a Medical Oncologist near Stanford, CA. An internist specializing in the diagnosis and treatment of various cancers and both benign and malignant tumors. This specialist determines and administers therapy for malignancies and collaborates with surgeons and radiation oncologists on additional cancer treatment options. Contact Dr. Telli to book an appointment today.
Is this Dr. Melinda Telli affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Telli is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Medical Oncologist?
Explore Medical Oncologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Melinda Telli accepting new patients in Stanford, CA?
Yes, Dr. Melinda Telli is accepting new patients at this time.
Does Dr. Melinda Telli offer online booking?
Please contact Dr. Telli's office for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Melinda Telli?
Please contact Dr. Telli's office for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Melinda Telli have?
Dr. Melinda Telli is certified by the American Board of Internal Medicine.
Other Medical Oncologist Near Stanford, CA
Medical Oncologist
Accepting patientsMedical Oncologist
Accepting patientsMedical Oncologist
Accepting patients